• Otsuka Pharmaceutical and Lundbeck present positive results showing reduced agitation in patients with Alzheimer's dementia treated with brexpiprazole at the 2022 Alzheimer's Association International Conference

    9 days ago - By San Diego Biotechnology

    SAN DIEGO--Otsuka Pharmaceutical Development & Commercialization, Inc. and H. Lundbeck A/S today presented positive results from a Phase 3 clinical trial of brexpiprazole in the treatment of agitation in patients with Alzheimer's...
    Read more ...